Treatment of osteonecrosis of the femoral head by botulinum toxin type A injection to the psoas muscle: A case report
Anesthesia and Pain Medicine
;
: 85-90, 2017.
Article
in English
| WPRIM
| ID: wpr-21257
ABSTRACT
Osteonecrosis of the femoral head (ONFH) can cause femoral head depression and cortical discontinuity. Treatment for ONFH remains challenging. We performed botulinum toxin type A injection to psoas major muscle in five patients with radiological femoral head collapse (Association Research Circulation Osseus classification stage III) who were non-responsive after two years of conservative treatment (tramadol 200 mg/day, mefenamic acid 1,000 mg/day). At two weeks after the procedure, their mean hip pain was decreased from 88 ± 0.4/100 mm to 22 ± 0.4/100 mm based on visual analogue scale (VAS). The pain was maintained at a minimum of 20/100 mm and a maximum of 30/100 mm in VAS for at least six weeks after the procedure. These values were mean ± SD. These patients were followed-up for 6 months. There was no exacerbation of pain from repeated (three times) botulinum toxin type A injection to the psoas major muscle.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Osteonecrosis
/
Botulinum Toxins
/
Mefenamic Acid
/
Psoas Muscles
/
Classification
/
Botulinum Toxins, Type A
/
Depression
/
Femur Head Necrosis
/
Head
/
Hip
Limits:
Humans
Language:
English
Journal:
Anesthesia and Pain Medicine
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS